This test is based on free circulating tumor DNA (ctDNA) in liquid biopsies, principally blood, while other matrixes are currently under validation (urine, saliva, vaginal swab, …).
In clinical trials, our personalized ctDNA assay can be used:
- To identify disease recurrence and potentially identify relapse drivers by monitoring the amount of ctDNA of treated patients and identifying escaping variants., allowing this way to change/initiate treatment earlier.
- To assess therapy response in the neoadjuvant setting to assess personalized therapies.
- To better characterize patients and optimize their selection or randomization for clinical trials.
Customization for each patient can be made by selecting a set of patient-specific variants, identified in the tumor by a previous genetic test (like our OncoSTRAT&GO solution or tests like FoundationOne® or FoundationACT® from Foundation Medicine, CGP+ from Caris Molecular Intelligence or Guardant360 from Guardant Health).
Our assay can then be composed of one or two sets of markers:
- A first set of markers consisting in a core panel addressing variants (SNV, Indel and CNV) or translocation. We have standard panels ranging from 10 to 40 genes but this core panel can be designed according to your genes of interest.
- The second set of biomarkers consists in patients’ specific variants which allow to monitor the heterogeneity of the response.
- Cost effective: combination of clinically validated variants and patient specific variants allows fast and robust treatment escape monitoring at a lower cost than large CDS gene panels. The panel can truly be used repeatedly on liquid biopsy samples.
- Sensitive: Relapses have been detected earlier than routine imaging technologies.
- Treatment finder: identify new targets if the cancer grows resistant to the current therapy.